P-glycoprotein and cancer: what do we currently know?

Heliyon. 2022 Oct 22;8(10):e11171. doi: 10.1016/j.heliyon.2022.e11171. eCollection 2022 Oct.

Abstract

Acquired resistance during cancer treatment is unfortunately a frequent event. There are several reasons for this, including the ability of the ATP-binding cassette transporters (ABC transporters), which are integral membrane proteins, to export chemotherapeutic molecules from the interior of the tumor cells. One important member of this family is the protein known as Permeability Glycoprotein (P-Glycoprotein, P-gp or ABCB1). Its clinical relevance relies mainly on the fact that the inhibition of P-gp and other ABC transporters could result in the reversal of the multidrug resistance (MDR) phenotype in some patients. Recently, other roles apart from being a key player in MDR, have emerged for P-gp. Therefore, this review discusses the relationship between P-gp and MDR, in addition to the possible role of this protein as a biomarker in cancer.

Keywords: ABC transporters; ABCB1; Cancer biomarkers; MDR phenotype; P-glycoprotein.

Publication types

  • Review